Garth L Nicolson

US Patent:

52624030, Nov 16, 1993

Filed:

Jul 10, 1990

Appl. No.:

7/550827

Inventors:

Garth L. Nicolson - Kingwood TX
Tatsuro Irimura - Tokyo, JP
Motowo Nakajima - Kamagaya, JP

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31725
C08B 3710

US Classification:

514 56

Abstract:

The present invention comprises a method for impeding the formation of tumor metastasis or tumor invasiveness in a host. Such inhibition comprises administration to the host of a glycosaminoglycan derivative substantially devoid of anticoagulation activity and is an effective inhibitory of heparanase activity. Such a glycosaminoglycan derivative may be provided by purchase or synthesis as directed herein. Parenteral administration to a tumor-bearing host of the glycosaminoglycan derivative results in the exposure of host-borne tumor cells thereto. Such exposure to effective levels of the derivative results in the inhibition of tumor heparanase activity and a lessening of invasiveness and metastatic spread. Heparin, a glycosaminoglycan particularly effective as a heparanase inhibitor and an anti-clotting agent, is a preferred glycosaminoglycan for derivatization. Upon derivatization according to the present invention heparin may be converted into a glycosaminglycan derivative substantially devoid of anticoagulant activity but yet being an effective inhibitor of heparanase activity.

US Patent:

50305590, Jul 9, 1991

Filed:

Apr 1, 1986

Appl. No.:

6/846938

Inventors:

Garth L. Nicolson - Kingwood TX
Susan M. North - Houston TX
Peter A. Steck - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

G01N 3353
G01N 33567
C07K 1514
C07K 114

US Classification:

435 723

Abstract:

Disclosed are monoclonal antibodies which react with human tumor cells, particularly metastatic human tumor cells, but not with normal human tissues tested. The monoclonal antibodies are prepared against a 580 kilodalton glycoprotein antigen, designated gp580, which is isolated from either rat or human tumor cells. Methods for isolating the glycoprotein antigen are disclosed as well. Moreover, techniques are disclosed for utilizing these antibodies both in the detection and in the prevention of human tumor lesions.

US Patent:

51644894, Nov 17, 1992

Filed:

May 23, 1988

Appl. No.:

7/197689

Inventors:

Garth L. Nicolson - Kingwood TX
Philip G. Cavanaugh - Houston TX

Assignee:

Board of Regents, University of Texas System - Austin TX

International Classification:

C07K 1514
C07K 1528

US Classification:

530397

Abstract:

The invention relates to the purification and characterization of growth stimulatory and inhibitory protein factors produced by various organs which appear to play a role in the successful formation of metastatic colonies of tumor cells. In particular, it has been found that syngeneic organs secrete protein growth stimulatory and inhibitory factors which can, at low concentrations, affect metastatic tumor cells. The ability of a malignant cell to respond to these factors is believed to be related to tumor cell metastasis to specific body organs. In particular a lung growth stimulatory glycoprotein having a molecular weight of approximately 66,000 daltons has been found to stimulate growth of lung-metastatic rat and human mammary tumor cells in serum deprived medium.

US Patent:

48595810, Aug 22, 1989

Filed:

Feb 20, 1987

Appl. No.:

7/012860

Inventors:

Garth L. Nicolson - Kingwood TX
Motowo Nakajima - Houston TX
Tatsuro Irimura - Bellaire TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 100

US Classification:

435 4

Abstract:

A solid phase substrate which yields soluble labeled products upon hydrolysis by a glycosaminoglycan endoglycosidase and methods of producing said substrate are comprised in the present invention. The solid phase substrate comprises glycosaminoglycan bearing labeled substances bound to amino groups. The labeled glycosaminoglycan substrate is reductively aminated at its reducing terminal end to produce an amine-terminus. The substrate is further coupled to an amino-reactive solid matrix through its amine-terminus. A method of producing the solid phase substrate comprises the steps of: at least partially N-desulfating or N-deacylating a glycosaminoglycan; labeling at least partially N-deacylated or N-desulfated glycosaminoglycan with a substance yielding detectable signals to produce labeled glycosaminoglycan; completely N-acylating the labeled glycosaminoglycan with acyl anhydride or acyl halide; reductively aminating a reducing terminal end of said labeled glycosaminoglycan to produce labeled amine-terminal glycosaminoglycan; and coupling, through its terminal amine, the labeled amine-terminal glycosaminoglycan to an amino-reactive solid phase support to produce the solid phase substrate. The solid phase substrate is usable to detect metastatic tumors by measurement of serum heparanase levels. The potential metastases of a tumor may also be determined by its heparanase levels.

US Patent:

53935349, Feb 28, 1995

Filed:

Apr 9, 1992

Appl. No.:

7/865549

Inventors:

Philip G. Cavanaugh - Houston TX
Garth L. Nicolson - Kingwood TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 35407

US Classification:

424553

Abstract:

A factor has been purified from rat liver homogenate which displays preferential growth inhibitory effects on non-liver metastasizing tumor cells. The purification steps include heat treatment, ammonium sulfate precipitation, anion exchange chromatography, hydrophobic interaction chromatography, cation exchange chromatography, gel filtration chromatography, and preparative isoelectric focusing. The growth inhibitor obtained has an apparent M. sub. r of 38 kD to 40 kD and a pI of 9. 1, it is not affected by reducing agents, and displays no biological TGF-b activity. This inhibitor exhibits less antiproliferative effect on liver metastasizing cells than on their non-liver metastasizing counterparts in two tumor systems: the murine RAW117 large cell lymphoma, and the human A375 melanoma.

US Patent:

20200268775, Aug 27, 2020

Filed:

May 8, 2020

Appl. No.:

16/870868

Inventors:

Garth L. Nicolson - Huntington Beach CA, US
Robert A. Settineri - Irvine CA, US
Gonzalo Ferreira de Mattos - Montevideo, UY
Paul C. Breeding - San Antonio TX, US

International Classification:

A61K 31/702
A61K 31/661
A61K 9/00
A23D 9/013
A61K 38/28
A61K 38/44
A61K 45/06
A61K 47/12
A61K 47/24
A61K 47/26
A61K 31/05
A61K 31/122
A61K 31/16
A61K 31/375
A61K 31/385
A61K 31/522
A61K 31/593
A61K 31/66
A61K 31/683
A61K 31/685
A61K 31/7028
A61K 31/716
A61K 31/733
A61K 33/22
A23L 29/10
A23L 29/244
A23L 33/105
A23L 33/115
A23L 33/12
A61P 39/06
A61P 21/00

Abstract:

A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating pain from overactive neurons. The phospholipid/inulin compositions were also shown to be effective in reducing depression and intestinal malfunctions including, but not limited to, diarrhea and constipation, and improving sleep pattern. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.